HTA Database - Search Results

Sort by Relevance

Search Results [1476 Hits] Selected Records [0 Hits] [Clear]

Year	Source	Title
2021	Health Information and Quality Authority (HIQA)	Health technology assessment of birth cohort testing for hepatitis C
2021	Health Information and Quality Authority (HIQA)	Rapid antigen testing for screening or surveillance of asymptomatic individuals to limit transmission of SARS-CoV-2
2021	Austrian Institute for Health Technology Assessment (AIHTA)	Stool DNA testing for colorectal cancer (CRC) screening
2021	Health Technology Wales (HTW)	Handheld single lead electrocardiogram devices to detect atrial fibrillation in older adults and those with intermittent episodes
2021	Health Information and Quality Authority (HIQA)	Review of international ethics frameworks used in policy-making in the context of screening
2021	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: efficacy and safety of onasemnogene abeparvovec, nusinersen and risdiplam for the treatment of spinal muscular atrophy]
2021	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: assessment of the relevance of newborn screening for spinal muscular atrophy]
2021	Swiss Federal Office of Public Health (FOPH)	Effectiveness and safety of vitamin B12 tests
2021	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of practice: care pathways leading to the diagnostic assessment of neurodevelopmental disorders in children 0-7 years old]
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Benefit assessment of medicinal products with new active ingredients according to section 35a SGB V: Blinatumomab (new therapeutic indication: B-precursor acute lymphoblastic leukaemia, relapsed or refractory, Ph+ CD19+)]
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Ivacaftor/Tezacaftor/Elexacaftor (Exceeding the € 50 Million Limit, Cystic Fibrosis, Combination Treatment with Ivacaftor in Patients 12 Years and Older (Heterozygous for F508del and MF Mutation))]
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Ivacaftor/Tezacaftor/Elexacaftor (exceeding the € 50 million limit, cystic fibrosis, combination treatment with Ivacaftor in patients 12 years and older (homozygous for F508del mutation))]
2021	Canadian Agency for Drugs and Technologies in Health (CADTH)	Prevention of tuberculosis reactivation
2021	Basque Office for Health Technology Assessment (OSTEBA)	[Efficacy of high flow oxygen therapy for the treatment of respiratory distress in children]
2021	Adelaide Health Technology Assessment (AHTA)	Guidelines for preparing assessments for the Medical Services Advisory Committee. Version 1.0
2021	Health Technology Wales (HTW)	Transcranial magnetic stimulation for the treatment of depression
2021	Institute for Clinical Effectiveness and Health Policy (IECS)	[Tafamidis for transthyretin amyloid cardiomyopathy]
2021	Canary Health Service	[Prenatal screening for toxoplasmosis]
2021	Health Sciences Institute in Aragon (IACS)	[Clinical effectiveness of sFlt-1 to PlGF ratio tests for the evaluation of preeclampsia]
2021	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	[Systematic review about effectiveness of digital pathology as a diagnostic tool for pathology and cytopathology]
2021	Canary Health Service	[Molecular markers for the detection of clinically significant prostate cancer]
2020	NIHR Health Technology Assessment programme	Annual mammographic screening to reduce breast cancer mortality in women from age 40 years: long-term follow-up of the UK Age RCT
2020	NIHR Health Technology Assessment programme	Pre-Operative Behavioural Intervention to Reduce Drinking before elective orthopaedic Surgery (Pre-Op BIRDS)
2020	NIHR Health Services and Delivery Research programme	Dementia and cognitive impairment in the older prison population of England and Wales: identifying individual need and developing a skilled, multi-agency workforce to deliver targeted and responsive services
2020	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Clinical Efectiveness of Newborn Screening for Inborn Errors of Metabolism by MS/ MS. Update and pilot study assessment: Maple Syrup Urine Disease; Isovaleric Acidaemia; Homocystinuria]
2020	Basque Office for Health Technology Assessment (OSTEBA)	[Neonatal hearing screening programmes: A systematic review of economic evaluation studies and descriptive analysis of Spanish regional programmes]
2020	NIHR Health Technology Assessment programme	Point-of-care creatinine tests to assess kidney function for outpatients requiring contrast-enhanced CT imaging: systematic reviews and economic evaluation
2020	Norwegian Institute of Public Health (NIPH)	Abdominal aorta aneurysm (AAA) screening of men aged 65
2020	Norwegian Institute of Public Health (NIPH)	Safety, clinical effectiveness, predictive accuracy and cost effectiveness of blood based tests for women with suspected preeclampsia: a health technology assessment
2020	Scottish Health Technologies Group (SHTG)	Second-generation colon capsule endoscopy (CCE-2) for the detection of colorectal polyps – SHTG Recommendation
2020	NIHR Health Services and Delivery Research programme	Understanding and improving experiences of care in hospital for people living with dementia, their carers and staff: three systematic reviews
2020	Health Technology Wales (HTW)	Rapid collaborative review on the diagnostic accuracy of molecular methods that detect the presence of the SARS-COV-2 virus in people with suspected COVID-19
2020	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: tomosynthesis and breast cancer: diagnostic evaluation and other uses]
2020	Austrian Institute for Health Technology Assessment (AIHTA)	Genetic testing in the context of familial hypercholesterolaemia management. Organisational and ethical implications (part 1), and economic aspects (part 2)
2020	Austrian Institute for Health Technology Assessment (AIHTA)	[Lung cancer screening in risk groups]
2020	Austrian Institute for Health Technology Assessment (AIHTA)	Lung cancer screening in risk groups: a review-update of the economic evidence (Part II)
2020	National Committee for Technology Incorporation (CONITEC)	[Newborn screening for congenital toxoplasmosis]
2020	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Comparative results of the different screening strategies used for T21, T18 and T13: adaptation of the EUnetHTA assessment]
2020	European Network for Health Technology Assessment (EUnetHTA)	Lung cancer screening in risk groups
2020	European Network for Health Technology Assessment (EUnetHTA)	Rapid collaborative review on the current role of antibody tests for novel coronavirus SARS-COV-2 in the management of the pandemic
2020	European Network for Health Technology Assessment (EUnetHTA)	Rapid collaborative review on the diagnostic accuracy of molecular methods that detect the presence of SARS-COV-2 virus in people with suspected COVID-19
2020	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: temperature screening for healthcare personnel
2020	Malaysian Health Technology Assessment (MaHTAS)	Programmatic management of latent tuberculosis infection
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Human papilloma virus (HPV) vaccine in patients with HPV lesions or infection]
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Digital tomosynthesis for breast cancer]
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Virtual colonoscopy for colorectal cancer screening in patients with diverticular disease]
2020	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	[Clinical effectiveness of pulse oximetry for neonatal screening of critical congenital heart diseases]
2020	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Burosumab (reassessment after the deadline: hypophosphataemia)]
2020	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Burosumab (new therapeutic indication: X-linked hypophosphataemia, ≥ 18 years)]
2020	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Givosiran (acute hepatic porphyria, ≥ 12 years)]
2020	Malaysian Health Technology Assessment (MaHTAS)	Hepatitis C virus screening and surveillance tests for dialysis patients
2020	Malaysian Health Technology Assessment (MaHTAS)	Strategies to eliminate mother to child transmission of hepatitis B in Malaysia
2020	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Volanesorsen]
2020	Canary Health Service	[Cost-effectiveness analysis of newborn screening for severe combined immunodeficiency]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Newborn screening for spinal muscular atrophy (SMA)]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Prostate cancer screening with the PSA test]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Lung cancer screening using low-dose computed tomography]
2020	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Screening and testing for COVID-19 before surgery
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Testicular cancer: does regular screening for men from the age of 16 lead to better treatment outcomes?]
2020	Health Information and Quality Authority (HIQA)	Evidence summary for non-contact thermal screening as an effective means of identifying cases of COVID-19
2019	NIHR Public Health Research (PHR) programme	A multi-centre individual-randomised controlled trial of screening and brief alcohol intervention to prevent risky drinking in young people aged 14-15 in a high school setting (SIPS JR-HIGH)
2019	NIHR Health Services and Delivery Research programme	Digital and online symptom checkers and assessment services for urgent care to inform a new digital platform: a systematic review
2019	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Screening and prevention programmes for children and adolescents from 6 to 14 years. Results from selected countries and recommendations from evidence-based guidelines
2019	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Screening for Diabetes mellitus: guideline recommendations
2019	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Screening programs for children and adolescents from 6 to 18 years. Results on selected countries, Austrian screening programmes and recommendations from evidence-based guidelines
2019	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Cervical Carcinoma Prevention - Implementation of an HPV screening test for early detection of cervical cancer in Austria
2019	Health Quality Ontario (HQO)	Noninvasive Prenatal Testing for Trisomies 21, 18, and 13, Sex Chromosome Aneuploidies, and Microdeletions: A Health Technology Assessment
2019	Health Sciences Institute in Aragon (IACS)	Detection of diabetes' complications. Diabetic retinopathy. Economic evaluation of ultra-wide field scanning laser
2019	Basque Office for Health Technology Assessment (OSTEBA)	[Indications, utility and use of ultrasound in primary care]
2019	Adelaide Health Technology Assessment (AHTA)	Alpha Thalassaemia genetic testing
2019	Health Technology Wales (HTW)	Pharmacogenetic testing to identify the risk of adverse reactions to anti-epileptic medications
2019	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: assessment of the relevance of newborn blood spot screening for biotinidase deficiency (BIOT)]
2019	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: relevance of low-dose computed tomography lung cancer screening]
2019	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: breast tomosynthesis and breast cancer screening]
2019	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: best strategies for reducing the risk of severe toxicities caused by dihydropyrimidine dehydrogenase deficiency]
2019	European Network for Health Technology Assessment (EUnetHTA)	Stool DNA testing for early detection of colorectal cancer
2019	European Network for Health Technology Assessment (EUnetHTA)	Screening for osteoporosis in the general population
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Kinanthropometric nutritional assessment]
2019	Canadian Agency for Drugs and Technologies in Health (CADTH)	HPV testing for primary cervical cancer screening: a health technology assessment
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Newborn screening for sickle cell disease]
2019	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Evidence on the personalization of population-based breast cancer screening]
2019	Health Information and Quality Authority (HIQA)	Systematic review of nutritional screening tools for adult patients in acute hospital settings. Nutrition screening and use of oral nutrition support for adults in the acute care setting
2018	NIHR Health Technology Assessment programme	UK Lung Cancer Screening Trial (UKLS) - Feasibility study and protocol development
2018	NIHR Health Technology Assessment programme	Screening women aged 65 years or over for abdominal aortic aneurysm: a modelling study and health economic evaluation
2018	NIHR Health Technology Assessment programme	What works to Increase attendance for Diabetic Retinopathy screening? An Evidence sYnthEsiS (WIDeR-EyeS)
2018	NIHR Health Technology Assessment programme	Combined feasibility and external pilot study to inform the design and conduct of the Fluids in Shock (FiSh) trial
2018	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Patient Health Questionnaire- 9, PHQ-9, for depression screening in adults]
2018	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Clinical effectiveness of newborn screening for severe combined immunodeficiency]
2018	NIHR Health Technology Assessment programme	Treatments for dry age-related macular degeneration and Stargardt disease: a systematic review
2018	NIHR Health Technology Assessment programme	What works to increase attendance for diabetic retinopathy screening? An evidence synthesis and economic analysis
2018	NIHR Health Technology Assessment programme	Screening women aged 65 years or over for abdominal aortic aneurysm: a modelling study and health economic evaluation
2018	NIHR Health Technology Assessment programme	Adjunctive colposcopy technologies for assessing suspected cervical abnormalities: systematic reviews and economic evaluation
2018	NIHR Health Technology Assessment programme	Low-dose computed tomography for lung cancer screening in high-risk populations: a systematic review and economic evaluation
2018	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Re-orientation of the Austrian parent-child preventive care programme. Part XI: Further development of the mother-child-pass: Screening recommendations of the expert working group for pregnancy, puerperium and early childhood (0-6 years)
2018	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	External stimulation of the trigeminal nerve for the prevention and acute treatment of episodic and chronic migraine
2018	Andalusian Health Technology Assessment Area (AETSA)	[Digital tomosynthesis in breast cancer: meta-analysis]
2018	Norwegian Institute of Public Health (NIPH)	Diagnostic accuracy, clinical effectiveness and budget impact of screening BRCA1/2 mutation carriers by MRI. A health technology assessment
2018	Penn Medicine Center for Evidence-based Practice (CEP)	Guidance for Prostate Cancer Screening
2018	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: use of the prostate-specific antigen (PSA) test in prostate cancer screening in Québec]
2018	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: mild traumatic brain injury, knowledge update in preparation for the revision of the ministerial orientations for mild traumatic brain injury (2005-2010)]